Strs Ohio invests $1.89 million in
Royalty Pharma PL. The company reports a
20% portfolio growth and holiday quarter receipts of $727M. The $2 billion
debt offering could revolutionize
RPRX's stock. A notable increase in wealth would be observed if an investor put $1000 in Royalty Pharma 15 years ago. Anticipation rises for the Investor Day event. Royalty Pharma's
$2 billion senior notes offering successful, even as its stocks require boosting. The company's
stock price target raised to $38. It has committed $300M to Zenas'
Obexelimab Program. However, Wall Street downgrades the stock to hold rating. Several investors increase their stake in the company, despite Q2
revenue estimates missing their mark.
Amgen's lung cancer drug royalty acquisition by Royalty Pharma could cost up to $950M. Financial groups trim their holdings, but Royalty Pharma acquires rights to
Breakthrough Lung Cancer Drug Imbelltra with $2.8B peak sales potential. The
stock's price is on an uptrend, reaching 52-week high at various points. Its
external manager acquisition got shareholder approval.
BofA securities raises the stock price target to $48.
Zenas BioPharma's Obexelimab receives $300M backing from Royalty Pharma. Company could offer significant upside risk/reward.
Royalty Pharma Stocks News Analytics from Wed, 12 Feb 2025 08:00:00 GMT to Sat, 20 Sep 2025 21:11:46 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -5
